Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy-Reference-Cited by-同舟云学术

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy

Published:2022-09 Issue:9 Volume:17 Page:1130-1136
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Kalchiem-Dekel Or,Falcon Christina J.,Bestvina Christine M.,Liu Dazhi,Kaplanis Lauren A.,Wilhelm Clare,Eichholz Jordan,Harada Guilherme,Wirth Lori J.,Digumarthy Subba R.,Lee Robert P.,Kadosh David,Mendelsohn Robin B.,Donington Jessica,Gainor Justin F.,Drilon Alexander,Lin Jessica J.

Funder

National Cancer Institute

LUNGevity Foundation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes;Drilon;Nat Rev Clin Oncol,2018

2. RET revisited: expanding the oncogenic portfolio;Mulligan;Nat Rev Cancer,2014

3. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance;Schram;Nat Rev Clin Oncol,2017

4. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer;Drilon;N Engl J Med,2020

5. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study;Gainor;Lancet Oncol,2021

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

2. RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future;Drugs;2024-07-13

3. Chylöser Aszites bei NSCLC: Nicht alles ist maligne, was maligne aussieht;Onkologische Welt;2024-07

4. Insights into highly selective RET inhibitors in medullary thyroid cancer;Current Opinion in Endocrine and Metabolic Research;2024-06

5. Peritoneal effusion: an uncommon adverse effect of selective RET inhibitors;Annals of Oncology;2024-05